Benefits of cell therapy for type 1 diabetes outweigh risks

The investigational cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes.

There is nothing patients [with diabetes] like more than freedom from dealing with the entire insulin issue.

This therapy can help some patients and will be incredibly meaningful to those who receive it.

Donislecel (Lantidra, CellTrans) — an allogeneic pancreatic islet cellular therapy — has been shown to increase insulin independence and decrease the number of severe hypoglycemic events among patients with difficult-to-control type 1 diabetes, based on pooled results of two open-label studies.

The therapy comprises islet cells isolated from a single donor pancreas. The final cultured cell product is transplanted through infusion in the hepatic portal vein via percutaneous or transvenous transhepatic access or — if these are not feasible —via laparoscopic or open surgical access.

The data on sustained insulin independence are compelling,

also The results meet the minimum 4-year insulin-independence benchmark for providing clinically impactful benefit that the panel had agreed to earlier.

Finally, The evidence suggests that many patients have benefited from this type of transplantation , even if the market size for this therapy might decline over time.

You are currently viewing Benefits of cell therapy for type 1 diabetes outweigh risks

Ali Achira MD

Dr. Ali Achira Dr. Ali Achira, MD is an endocrinologist in Dearborn and in Taylor, Michigan. He is currently licensed to practice medicine in Michigan. He is affiliated with DMC Harper University Hospital. He is board certified in Internal Medicine. Board certified in Endocrinology & Diabetes, and board certified in Obesity medicine. He manages Diabetes, Thyroid, osteoporosis, Obesity and other endocrinology disorders.